AEON vs. ATAI, ENTA, XBIT, IMMP, ME, DSGN, ACRV, FHTX, ALDX, and TSVT
Should you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include Atai Life Sciences (ATAI), Enanta Pharmaceuticals (ENTA), XBiotech (XBIT), Immutep (IMMP), 23andMe (ME), Design Therapeutics (DSGN), Acrivon Therapeutics (ACRV), Foghorn Therapeutics (FHTX), Aldeyra Therapeutics (ALDX), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical preparations" industry.
Atai Life Sciences (NASDAQ:ATAI) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.
28.4% of Atai Life Sciences shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 31.2% of Atai Life Sciences shares are held by company insiders. Comparatively, 20.0% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, AEON Biopharma had 1 more articles in the media than Atai Life Sciences. MarketBeat recorded 5 mentions for AEON Biopharma and 4 mentions for Atai Life Sciences. AEON Biopharma's average media sentiment score of 0.43 beat Atai Life Sciences' score of 0.06 indicating that Atai Life Sciences is being referred to more favorably in the media.
Atai Life Sciences has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.
Atai Life Sciences received 321 more outperform votes than AEON Biopharma when rated by MarketBeat users. However, 100.00% of users gave AEON Biopharma an outperform vote while only 65.99% of users gave Atai Life Sciences an outperform vote.
AEON Biopharma has lower revenue, but higher earnings than Atai Life Sciences.
Atai Life Sciences presently has a consensus target price of $10.50, indicating a potential upside of 568.79%. AEON Biopharma has a consensus target price of $6.00, indicating a potential upside of 279.75%. Given AEON Biopharma's higher probable upside, equities research analysts clearly believe Atai Life Sciences is more favorable than AEON Biopharma.
AEON Biopharma has a net margin of 0.00% compared to AEON Biopharma's net margin of -12,810.51%. Atai Life Sciences' return on equity of 0.00% beat AEON Biopharma's return on equity.
Summary
Atai Life Sciences beats AEON Biopharma on 9 of the 14 factors compared between the two stocks.
Get AEON Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AEON Biopharma Competitors List
Related Companies and Tools
